In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...